Advertisement

BioDrugs

, Volume 23, Issue 5, pp 289–304 | Cite as

Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor

Current Status and Future Challenges in Cancer Therapy
  • Jerry Y. Hsu
  • Heather A. Wakelee
Review Article

Abstract

The use of monoclonal antibodies targeting the vascular endothelial growth factor (VEGF) pathway has been a significant addition to cancer therapy. One of the VEGF family members, VEGF-A (commonly referred to as VEGF), has been demonstrated to be important in angiogenesis. Although the mechanism of action of these antibodies is still under study, the anti-VEGF antibody bevacizumab has been approved for treatment of various solid cancers including colorectal, lung, and breast cancers as well as glioblastoma and renal cell carcinoma. Addition of bevacizumab to chemotherapy as adjuvant therapy in colorectal cancer did not improve disease-free survival. Bevacizumab is being tested in other clinical settings such as adjuvant therapy, maintenance therapy, and in combination with both chemotherapy and other targeted agents such as the epidermal growth factor receptor kinase inhibitor erlotinib. In addition to bevacizumab, other antibody-based therapies targeting the VEGF pathway are being tested. Ramucirumab and IMC-18F1 are monoclonal antibodies that target the VEGF receptors VEGFR-2 and VEGFR-1, respectively. Aflibercept (VEGF-Trap), a peptide-antibody fusion targeting VEGF ligand, is being tested in clinical trials. Much research is focused on identifying biomarkers to predict which patients will benefit from anti-VEGF therapy. Recent results suggest that VEGF single nucleotide polymorphisms may be predictive of patient response to bevacizumab. Improved imaging modalities such as dynamic contrast-enhanced MRI (DCE-MRI) can better characterize the efficacy of anti-angiogenic agents. As anti-VEGF treatments such as bevacizumab have been integrated into the treatment of many different types of cancers, the development of bevacizumab-resistant tumors has become more common. Recent studies show that targeting other angiogenesis signaling pathways such as platelet-derived growth factor-C (PDGF-C), Bombina variagata peptide 8 (Bv8, also known as prokineticin-2), and VEGFR-3 may lead to enhanced response in anti-VEGF resistant tumors. In the future, tailored treatments consisting of combinations of chemotherapy, other targeted therapies, and anti-angiogenesis agents will hopefully result in better patient outcomes.

Keywords

Vascular Endothelial Growth Factor Bevacizumab Sorafenib Sunitinib Cetuximab 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

No sources of funding were used to assist in the preparation of this review. Jerry Hsu is supported by a Walter and Idun Berry Fellowship. Heather Wakelee receives research support from Genentech, Lilly Oncology, Regeneron, Novartis, Exelixis, and Cell Therapeutics, Inc.

References

  1. 1.
    Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002 Oct; 2(10): 795–803PubMedCrossRefGoogle Scholar
  2. 2.
    Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005 Feb 10; 23(5): 1011–27PubMedCrossRefGoogle Scholar
  3. 3.
    Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003 Jun; 9(6): 669–76PubMedCrossRefGoogle Scholar
  4. 4.
    Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008 Aug; 8(8): 579–91PubMedCrossRefGoogle Scholar
  5. 5.
    Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000 Sep 14; 407(6801): 249–57PubMedCrossRefGoogle Scholar
  6. 6.
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 Jun 3; 350(23): 2335–42PubMedCrossRefGoogle Scholar
  7. 7.
    Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008 Apr 20; 26(12): 2013–9PubMedCrossRefGoogle Scholar
  8. 8.
    Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007 Apr 20; 25(12): 1539–44PubMedCrossRefGoogle Scholar
  9. 9.
    Wolmark N, Yothers G, O'Connell M, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08 [abstract LBA4]. J Clin Oncol 2009; 27 (18 Suppl.): 793sGoogle Scholar
  10. 10.
    Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006 Dec 14; 355(24): 2542–50PubMedCrossRefGoogle Scholar
  11. 11.
    Reck M, Von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009 Feb 2; 27(8): 1227–34PubMedCrossRefGoogle Scholar
  12. 12.
    Jones D. Avastin-Tarceva combination fails in lung cancer. Nat Biotechnol 2009 Feb; 27(2): 108–9PubMedCrossRefGoogle Scholar
  13. 13.
    Miller VA, O'Connor P, Soh C, et al. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) [abstract LBA8002]. American Society of Clinical Oncology (ASCO) Annual Meeting 2009; 2009 May 29–Jun 2; Orlando (FL)Google Scholar
  14. 14.
    Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007 Dec 27; 357(26): 2666–76PubMedCrossRefGoogle Scholar
  15. 15.
    Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO [abstract LBA1011]. American Society of Clinical Oncology (ASCO) Annual Meeting 2008; 2008 May 30–Jun 3; Chicago (IL)Google Scholar
  16. 16.
    Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) [abstract 1005]. J Clin Oncol 2009; 27 (15 Suppl.): 42sCrossRefGoogle Scholar
  17. 17.
    Clinicaltrials.gov. A study to evaluate the safety and efficacy of bevacizumab in combination with chemotherapy in previously treated metastatic breast cancer (RIBBON 2) [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00281697?term=NCT00281697&rank=1 [Accessed 2009 Aug 12]
  18. 18.
    Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005 Feb 1; 23(4): 792–9PubMedCrossRefGoogle Scholar
  19. 19.
    Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007 Dec 22; 370(9605): 2103–11PubMedCrossRefGoogle Scholar
  20. 20.
    Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008 Nov 20; 26(33): 5422–8PubMedCrossRefGoogle Scholar
  21. 21.
    Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) [abstract 4508]. J Clin Oncol 2007; 25 (18 Suppl.): 4508Google Scholar
  22. 22.
    Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003 Jan 1; 21(1): 60–5PubMedCrossRefGoogle Scholar
  23. 23.
    Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009 Feb 5; 360(6): 563–72PubMedCrossRefGoogle Scholar
  24. 24.
    Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009 Feb; 20(2): 227–30PubMedCrossRefGoogle Scholar
  25. 25.
    Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009 Feb 10; 27(5): 672–80PubMedCrossRefGoogle Scholar
  26. 26.
    Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007 Oct 10; 25(29): 4557–61PubMedCrossRefGoogle Scholar
  27. 27.
    Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009 May 4; 27(20): 3385–90PubMedCrossRefGoogle Scholar
  28. 28.
    Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004 Jun 1; 22(11): 2184–91PubMedCrossRefGoogle Scholar
  29. 29.
    Hainsworth J, Herbst RS. A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab in combination with erlotinib compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line therapy (BeTa) [abstract]. J Thorac Oncol 2008; 3(11): S302Google Scholar
  30. 30.
    Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008 Jan 1; 26(1): 60–5PubMedCrossRefGoogle Scholar
  31. 31.
    Wakelee HA, Dahlberg SE, Brahmer JR, et al. Increased benefit from bevacizumab (BEV) in younger women with advanced NSCLC on Eastern Cooperative Oncology Group (ECOG) 4599 [abstract]. J Thorac Oncol 2008; 3(11): S282Google Scholar
  32. 32.
    Lynch T, Brahmer J, Fischbach N, et al. Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS) [abstract 8077]. American Society of Clinical Oncology (ASCO) Annual Meeting 2008; 2008 May 30–Jun 3; Chicago (IL)Google Scholar
  33. 33.
    Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2008 Dec 29; 27(5): 740–5PubMedCrossRefGoogle Scholar
  34. 34.
    A study to evaluate bevacizumab alone or in combination with irinotecan for treatment of glioblastoma multiforme (BRAIN) [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00345163 [Accessed 2009 Aug 12]
  35. 35.
    US FDA. Bevacizumab injection [online]. Available from URL: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm149364.htm [Accessed 2009 Aug 12]
  36. 36.
    Kamoun WS, Ley CD, Farrar CT, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009 May 20; 27(15): 2542–52PubMedCrossRefGoogle Scholar
  37. 37.
    Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 Jul 31; 349(5): 427–34PubMedCrossRefGoogle Scholar
  38. 38.
    Escudier B, Bellmunt J, Negrier S, et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) +interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC) [abstract 5020]. J Clin Oncol 2009; 27 (15 Suppl.): 239sCrossRefGoogle Scholar
  39. 39.
    Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206 [abstract LBA5019]. J Clin Oncol 2009; 27 (18 Suppl.): 798sGoogle Scholar
  40. 40.
    National Cancer Institute. FDA approval for bevacizumab [online]. Available from URL: http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab [Accessed 2009 Aug 31]
  41. 41.
    Karrison T, Kindler HL, Gandara DR, et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM) [abstract 7526]. J Clin Oncol 2007; 25 (18 Suppl.): 7526Google Scholar
  42. 42.
    Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008 Aug 15; 113(4): 808–14PubMedCrossRefGoogle Scholar
  43. 43.
    Griesinger F, Laskin JJ, Pavlakis N. Safety of first-line bevacizumab-based therapy with concomitant cardiovascular or anticoagulation medication in advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in MO19390 (SAiL) [abstract 8049]. American Society of Clinical Oncology (ASCO) Annual Meeting 2008; 2008 May 30–Jun 3; Chicago (IL)Google Scholar
  44. 44.
    Akerley WL, Langer C, Oh Y, et al. Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer [abstract 8043]. American Society of Clinical Oncology (ASCO) Annual Meeting 2008; 2008 May 30–Jun 3; Chicago (IL)Google Scholar
  45. 45.
    Sandler AB, Schiller JH, Gray R, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol 2009 Mar 20; 27(9): 1405–12PubMedCrossRefGoogle Scholar
  46. 46.
    Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20Suppl. 4: 61–3PubMedGoogle Scholar
  47. 47.
    Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009 Jan 12; 27(6): 843–50PubMedCrossRefGoogle Scholar
  48. 48.
    Sessa C, Guibal A, Del Conte G, et al. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol 2008 Jul; 5(7): 378–91PubMedCrossRefGoogle Scholar
  49. 49.
    Krupitskaya Y, Wakelee HA. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs 2009 Jun; 10(6): 597–605PubMedGoogle Scholar
  50. 50.
    Spratlin JL, Gore L, Camidge DR, et al. A phase I, pharmacological and biological study of weekly IMC-1121B, a recombinant human IgG 1 monoclonal antibody (MAb), targeting vascular endothelial growth factor receptor 2 (VEGFR-2), in patients (pts) with advanced solid tumors [abstract A33]. AACR-NCI-EORTC International Conference; 2007 Oct 22; San Francisco (CA)Google Scholar
  51. 51.
    Wu Y, Zhong Z, Huber J, et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res 2006 Nov 1; 12(21): 6573–84PubMedCrossRefGoogle Scholar
  52. 52.
    Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008 Oct 1; 26(28): 4672–8PubMedCrossRefGoogle Scholar
  53. 53.
    Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008 Aug 1; 26(22): 3709–14PubMedCrossRefGoogle Scholar
  54. 54.
    Cannistra SA. Challenges and pitfalls of combining targeted agents in phase I studies. J Clin Oncol 2008 Aug 1; 26(22): 3665–7PubMedCrossRefGoogle Scholar
  55. 55.
    Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008 Jan 20; 26(3): 374–9PubMedCrossRefGoogle Scholar
  56. 56.
    Tappenden P, Jones R, Paisley S, et al. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer 2007 Nov; 43(17): 2487–94PubMedCrossRefGoogle Scholar
  57. 57.
    Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008 Jun 20; 26(18): 2992–8PubMedCrossRefGoogle Scholar
  58. 58.
    Thomas AL, Morgan B, Horsfield MA, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005 Jun 20; 23(18): 4162–71PubMedCrossRefGoogle Scholar
  59. 59.
    Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007 Oct 20; 25(30): 4714–21PubMedCrossRefGoogle Scholar
  60. 60.
    Longo R, Gasparini G. Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol 2007 Jul; 60(2): 151–70PubMedCrossRefGoogle Scholar
  61. 61.
    Longo R, Gasparini G. Anti-VEGF therapy: the search for clinical biomarkers. Expert Rev Mol Diagn 2008 May; 8(3): 301–14PubMedCrossRefGoogle Scholar
  62. 62.
    Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006 Jan 10; 24(2): 217–27PubMedCrossRefGoogle Scholar
  63. 63.
    Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005 Jul 6; 97(13): 981–9PubMedCrossRefGoogle Scholar
  64. 64.
    Dowlati A, Gray R, Sandler AB, et al. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab: an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008 Mar 1; 14(5): 1407–12PubMedCrossRefGoogle Scholar
  65. 65.
    Zhang W, Dahlberg SE, Yang D, et al. Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: subset pharmacogenetic analysis of ECOG 4599 [abstract 8032]. J Clin Oncol 2009; 27 (15 Suppl.): 414sCrossRefGoogle Scholar
  66. 66.
    Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009; 27(18): 3020–6PubMedCrossRefGoogle Scholar
  67. 67.
    Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005 Nov 1; 23(31): 8136–9PubMedCrossRefGoogle Scholar
  68. 68.
    Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008 Aug; 8(8): 592–603PubMedCrossRefGoogle Scholar
  69. 69.
    Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009 Mar 3; 15(3): 220–31PubMedCrossRefGoogle Scholar
  70. 70.
    Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009 Mar 3; 15(3): 232–9PubMedCrossRefGoogle Scholar
  71. 71.
    Crawford Y, Kasman I, Yu L, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009 Jan 6; 15(1): 21–34PubMedCrossRefGoogle Scholar
  72. 72.
    Shojaei F, Wu X, Zhong C, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007 Dec 6; 450(7171): 825–31PubMedCrossRefGoogle Scholar
  73. 73.
    Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008 Jul 31; 454(7204): 656–60PubMedCrossRefGoogle Scholar
  74. 74.
    Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009; 27(18): 3027–35PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.Department of Medicine, Division of Oncology, Stanford Cancer CenterStanford UniversityStanfordUSA

Personalised recommendations